Equities

Allarity Therapeutics Inc

ALLR:NAQ

Allarity Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.21
  • Today's Change-0.05 / -2.21%
  • Shares traded332.76k
  • 1 Year change-99.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.82m
  • Incorporated2021
  • Employees5.00
  • Location
    Allarity Therapeutics Inc24 School St., 2Nd FloorBOSTON 02108United StatesUSA
  • Phone+1 (401) 426-4664
  • Fax+1 (302) 655-5049
  • Websitehttps://allarity.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GB Sciences Inc0.00-1.64m2.85m2.00---------0.0041-0.00410.00-0.01310.00----0.00-597.54-31.80---297.29-----------6.49--------60.24------
TNF Pharmaceuticals Inc0.00-7.07m3.01m9.00--0.1296-----5.53-5.530.0010.280.00----0.00-25.59-76.20-31.13-84.38--7.64---4,290.96----0.00------49.15------
Phio Pharmaceuticals Corp0.00-8.68m3.06m8.00--0.48-----23.77-23.770.007.400.00----0.00-98.62-71.92-126.86-84.15-------253,785.70----0.00------5.70--0.00--
Allarity Therapeutics Inc0.00-12.82m3.19m5.00--0.1331-----2,217.58-2,217.580.0016.980.00----0.00-52.54---110.73--------------0.0626------3.02------
CTT Pharmaceutical Holdings Inc0.00-1.67m3.22m0.00--1.73-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Revelation Biosciences Inc0.00-15.90m3.23m9.00--1.24-----29.75-29.750.000.69390.00----0.00-112.35---253.32--------------0.00------98.89------
Bone Biologics Corp0.00-5.12m3.28m2.00--0.823-----10.26-10.260.002.210.00----0.00-94.66-98.31-119.03--------------0.00-------502.76------
Halberd Corp281.24k25.34k3.31m3.002.24--130.3311.760.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Lipella Pharmaceuticals Inc507.20k-4.14m3.40m5.00--1.90--6.71-0.6188-0.61880.0740.2240.1788--16.01101,440.00-146.02---169.27-------816.72------0.00--144.15---77.81------
Tharimmune Inc0.00-8.88m3.44m2.00--0.4899-----55.46-55.460.006.110.00----0.00-138.06---181.81--------------0.00-------9.98------
Talis Biomedical Corp408.00k-51.03m3.46m99.00--0.0712--8.49-28.02-28.020.22426.690.0042--1.534,121.21-52.13-68.18-57.23-74.2295.10---12,506.37-1,615.96----0.00---55.65-2.2445.13---1.83--
Petros Pharmaceuticals Inc4.12m-20.64m3.60m21.00--0.4323--0.8747-6.54-6.541.000.9880.15290.67951.89196,223.30-26.18-32.43-39.25-68.0570.2162.04-171.23-201.701.26--0.4539---2.83-16.1531.06------
Data as of Sep 20 2024. Currency figures normalised to Allarity Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.